Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.
Novo Nordisk is a leader in obesity care, helping advance the understanding and management of obesity as a chronic disease. Changing Obesity™ is Novo Nordisk’s long-term commitment to – together with our partners – improve the lives of people with obesity, by changing how the world sees, prevents and treats obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 43,200 employees in 80 countries and markets its products in more than 170 countries.
VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. VIVUS is the manufacturer of Qsiva® (phentermine and topiramate extended-release) capsules CIV